Beyond neuromuscular activity: botulinum toxin type A exerts direct central action on spinal control of movement

Eur J Pharmacol. 2024 Jan 5:962:176242. doi: 10.1016/j.ejphar.2023.176242. Epub 2023 Dec 3.

Abstract

Overt muscle activity and impaired spinal locomotor control hampering coordinated movement is a hallmark of spasticity and movement disorders like dystonia. While botulinum toxin A (BoNT-A) standard therapy alleviates mentioned symptoms presumably due to its peripheral neuromuscular actions alone, the aim of present study was to examine for the first time the toxin's trans-synaptic activity within central circuits that govern the skilled movement. The rat hindlimb motor pools were targeted by BoNT-A intrasciatic bilateral injection (2 U per nerve), while its trans-synaptic action on premotor inputs was blocked by intrathecal BoNT-A-neutralising antitoxin (5 i.u.). Effects of BoNT-A on coordinated and high intensity motor tasks (rotarod, beamwalk swimming), and localised muscle weakness (digit abduction, gait ability) were followed until their substantial recovery by day 56 post BoNT-A. Later, (day 62-77) the BoNT-A effects were examined in unilateral calf muscle spasm evoked by tetanus toxin (TeNT, 1.5 ng). In comparison to peripheral effect alone, combined peripheral and central trans-synaptic BoNT-A action induced a more prominent and longer impairment of different motor tasks, as well as the localised muscle weakness. After near-complete recovery of motor functions, the BoNT-A maintained the ability to reduce the experimental calf spasm evoked by tetanus toxin (TeNT 1.5 ng, day 62) without altering the monosynaptic reflex excitability. These results indicate that, in addition to muscle terminals, BoNT-A-mediated control of hyperactive muscle activity in movement disorders and spasticity may involve the spinal premotor inputs and central circuits participating in the skilled locomotor performance.

Keywords: Axonal transport; Botulinum toxin type A; Motor control; Spinal cord; Trans-synaptic effect.

MeSH terms

  • Animals
  • Botulinum Toxins, Type A* / pharmacology
  • Movement
  • Movement Disorders*
  • Muscle Weakness
  • Neuromuscular Agents* / pharmacology
  • Rats
  • Tetanus Toxin

Substances

  • Botulinum Toxins, Type A
  • Tetanus Toxin
  • Neuromuscular Agents